share_log

Agios Pharmaceuticals Analyst Ratings

Agios Pharmaceuticals Analyst Ratings

Agios 制药分析师评级
Benzinga ·  2023/08/07 11:42
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/07/2023 24.32% JP Morgan $33 → $32 Maintains Neutral
06/27/2023 63.17% RBC Capital $40 → $42 Maintains Outperform
02/03/2023 59.29% Piper Sandler → $41 Initiates Coverage On → Overweight
12/01/2022 28.21% JP Morgan $48 → $33 Maintains Neutral
11/17/2022 24.32% Goldman Sachs $17 → $32 Upgrades Sell → Neutral
08/05/2022 43.75% SVB Leerink $33 → $37 Maintains Outperform
07/27/2022 28.21% SVB Leerink → $33 Upgrades Market Perform → Outperform
05/24/2022 -37.84% Goldman Sachs $20 → $16 Maintains Sell
05/17/2022 28.21% SVB Leerink $30 → $33 Maintains Market Perform
03/07/2022 -10.64% Goldman Sachs $37 → $23 Maintains Sell
03/03/2022 272.96% HC Wainwright & Co. $98 → $96 Maintains Buy
02/25/2022 160.3% RBC Capital $61 → $67 Maintains Outperform
02/24/2022 272.96% HC Wainwright & Co. $98 → $96 Maintains Buy
02/22/2022 16.55% SVB Leerink $32 → $30 Maintains Market Perform
02/18/2022 280.73% HC Wainwright & Co. $95 → $98 Maintains Buy
02/16/2022 70.94% Canaccord Genuity $52 → $44 Maintains Buy
12/03/2021 109.79% B of A Securities → $54 Initiates Coverage On → Buy
11/18/2021 63.17% SVB Leerink $50 → $42 Maintains Market Perform
11/04/2021 269.08% HC Wainwright & Co. $93 → $95 Maintains Buy
07/30/2021 261.31% HC Wainwright & Co. $88 → $93 Maintains Buy
07/30/2021 51.52% Goldman Sachs $58 → $39 Downgrades Neutral → Sell
07/01/2021 — Raymond James Initiates Coverage On → Market Perform
06/10/2021 241.88% HC Wainwright & Co. → $88 Initiates Coverage On → Buy
04/30/2021 152.53% Canaccord Genuity $57 → $65 Maintains Buy
03/01/2021 109.79% JP Morgan → $54 Downgrades Overweight → Neutral
02/26/2021 94.25% SVB Leerink $55 → $50 Downgrades Outperform → Market Perform
01/27/2021 113.68% SVB Leerink $51 → $55 Maintains Outperform
12/28/2020 121.45% Canaccord Genuity $70 → $57 Maintains Buy
12/09/2020 136.99% SVB Leerink $67 → $61 Maintains Outperform
10/22/2020 78.71% Barclays → $46 Upgrades Equal-Weight → Overweight
10/19/2020 168.07% Needham $71 → $69 Maintains Buy
10/19/2020 171.95% Canaccord Genuity $72 → $70 Maintains Buy
10/19/2020 160.3% SVB Leerink $72 → $67 Maintains Outperform
10/19/2020 183.61% Piper Sandler $80 → $73 Maintains Overweight
07/31/2020 179.72% Cantor Fitzgerald $70 → $72 Maintains Overweight
06/15/2020 179.72% SVB Leerink $70 → $72 Maintains Outperform
06/15/2020 191.38% Citigroup $64 → $75 Maintains Buy
05/04/2020 218.57% JP Morgan $72 → $82 Maintains Overweight
03/04/2020 94.25% Barclays → $50 Initiates Coverage On → Equal-Weight
02/14/2020 171.95% Cantor Fitzgerald $64 → $70 Reiterates → Overweight
12/09/2019 90.37% BMO Capital $45 → $49 Maintains Outperform
12/04/2019 164.18% JP Morgan $80 → $68 Maintains Overweight
11/26/2019 148.64% Cantor Fitzgerald → $64 Initiates Coverage On → Overweight
11/05/2019 148.64% Citigroup $80 → $64 Maintains Buy
09/23/2019 — Guggenheim Upgrades Neutral → Buy
09/12/2019 74.83% BMO Capital → $45 Initiates Coverage On → Outperform
05/23/2019 113.68% Goldman Sachs → $55 Assumes → Neutral
02/20/2019 — Oppenheimer Assumes → Perform
02/15/2019 210.8% Leerink Swann → $80 Upgrades Market Perform → Outperform
09/25/2018 210.8% Leerink Swann → $80 Initiates Coverage On → Market Perform
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
08/07/2023 24.32% 摩根大通 $33→$32 维护 中性
2023年6月27日 63.17% 加拿大皇家银行资本 $40→$42 维护 跑赢大盘
02/03/2023 59.29% 派珀·桑德勒 →$41 开始承保 →超重
12/01/2022 28.21% 摩根大通 $48→$33 维护 中性
2022年11月17日 24.32% 高盛 $17→$32 升级 卖出→中性
08/05/2022 43.75% SVB Leerink $33→$37 维护 跑赢大盘
07/27/2022 28.21% SVB Leerink →$33 升级 市场表现优于→
2022年05月24日 -37.84% 高盛 $20→$16 维护 卖
2022/05/17 28.21% SVB Leerink $30→$33 维护 市场表现
03/07/2022 -10.64% 高盛 $37→$23 维护 卖
03/03/2022 272.96% HC Wainwright公司 $98→$96 维护 买
02/25/2022 160.3% 加拿大皇家银行资本 $61→$67 维护 跑赢大盘
02/24/2022 272.96% HC Wainwright公司 $98→$96 维护 买
02/22/2022 16.55% SVB Leerink $32→$30 维护 市场表现
02/18/2022 280.73% HC Wainwright公司 $95→$98 维护 买
02/16/2022 70.94% 卡纳科特·格纳奇 $52→$44 维护 买
12/03/2021 109.79% B of A证券 →$54 开始承保 →购买
2021年11月18日 63.17% SVB Leerink $50→$42 维护 市场表现
11/04/2021 269.08% HC Wainwright公司 $93→$95 维护 买
07/30/2021 261.31% HC Wainwright公司 $88→$93 维护 买
07/30/2021 51.52% 高盛 $58→$39 评级下调 中性→销售
07/01/2021 - 雷蒙德·詹姆斯 开始承保 →市场表现
2021/10/06 241.88% HC Wainwright公司 →$88 开始承保 →购买
04/30/2021 152.53% 卡纳科特·格纳奇 $57→$65 维护 买
03/01/2021 109.79% 摩根大通 →$54 评级下调 超重→中性
02/26/2021 94.25% SVB Leerink $55→$50 评级下调 跑赢→市场表现
2021/01/27 113.68% SVB Leerink $51→$55 维护 跑赢大盘
12/28/2020 121.45% 卡纳科特·格纳奇 $70→$57 维护 买
12/09/2020 136.99% SVB Leerink $67→$61 维护 跑赢大盘
10/22/2020 78.71% 巴克莱 →$46 升级 等重→超重
10/19/2020 168.07% 李约瑟 $71→$69 维护 买
10/19/2020 171.95% 卡纳科特·格纳奇 $72→$70 维护 买
10/19/2020 160.3% SVB Leerink $72→$67 维护 跑赢大盘
10/19/2020 183.61% 派珀·桑德勒 $80→$73 维护 超重
07/31/2020 179.72% 康托·菲茨杰拉德 $70→$72 维护 超重
2020/06/15 179.72% SVB Leerink $70→$72 维护 跑赢大盘
2020/06/15 191.38% 花旗集团 $64→$75 维护 买
05/04/2020 218.57% 摩根大通 $72→$82 维护 超重
03/04/2020 94.25% 巴克莱 →$50 开始承保 →等重
02/14/2020 171.95% 康托·菲茨杰拉德 $64→$70 重申 →超重
2019年12月09日 90.37% 蒙特利尔银行资本 $45→$49 维护 跑赢大盘
2019/12/04 164.18% 摩根大通 $80→$68 维护 超重
2019年11月26日 148.64% 康托·菲茨杰拉德 →$64 开始承保 →超重
2019年11月05日 148.64% 花旗集团 $80→$64 维护 买
2019年09月23日 - 古根海姆 升级 中性→购买
2019/12/09 74.83% 蒙特利尔银行资本 →$45 开始承保 →跑赢大盘
2019年05月23日 113.68% 高盛 →$55 假设 →中性
2019年02月20日 - 奥本海默 假设 →性能
2019年02月15日 210.8% 利林克·斯旺 →$80 升级 市场表现优于→
2018年09月25日 210.8% 利林克·斯旺 →$80 开始承保 →市场表现

What is the target price for Agios Pharmaceuticals (AGIO)?

Agios制药(Agio)的目标价是多少？

The latest price target for Agios Pharmaceuticals (NASDAQ: AGIO) was reported by JP Morgan on August 7, 2023. The analyst firm set a price target for $32.00 expecting AGIO to rise to within 12 months (a possible 24.32% upside). 5 analyst firms have reported ratings in the last year.

纳斯达克(Agios PharmPharmticals)的最新目标价是由摩根大通于2023年8月7日报道的。这家分析公司将目标价定为32.00美元，预计Agio将在12个月内上涨(可能上涨24.32%)。去年有5家分析公司公布了评级。

What is the most recent analyst rating for Agios Pharmaceuticals (AGIO)?

分析师对Agios制药公司(Agio)的最新评级是多少？

The latest analyst rating for Agios Pharmaceuticals (NASDAQ: AGIO) was provided by JP Morgan, and Agios Pharmaceuticals maintained their neutral rating.

纳斯达克(Sequoia Capital：AGIO)的最新分析师评级由摩根大通提供，Agios制药维持中性评级。

When is the next analyst rating going to be posted or updated for Agios Pharmaceuticals (AGIO)?

Agios PharmPharmticals(Agio)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Agios Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Agios Pharmaceuticals was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Agios制药公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Agios制药的上一次评级是在2023年8月7日提交的，所以你应该预计下一次评级将在2024年8月7日左右的某个时候公布。

Is the Analyst Rating Agios Pharmaceuticals (AGIO) correct?

分析师对Agios制药(Agio)的评级正确吗？

While ratings are subjective and will change, the latest Agios Pharmaceuticals (AGIO) rating was a maintained with a price target of $33.00 to $32.00. The current price Agios Pharmaceuticals (AGIO) is trading at is $25.74, which is out of the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的Agios制药(Agio)评级维持不变，目标价在33.00美元至32.00美元之间。Agios制药(Agio)目前的交易价格为25.74美元，超出了分析师的预测区间。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发